CSL (OTCMKTS:CSLLY) Shares Gap Up – What’s Next?

Shares of CSL Limited Sponsored ADR (OTCMKTS:CSLLY) gapped up before the market opened on Monday . The stock had previously closed at $26.0550, but opened at $28.00. CSL shares last traded at $26.19, with a volume of 5,146 shares.

Analyst Ratings Changes

A number of equities research analysts recently commented on CSLLY shares. Zacks Research raised shares of CSL from a “strong sell” rating to a “hold” rating in a research note on Monday, December 29th. Royal Bank Of Canada lowered shares of CSL from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

CSL Stock Down 1.0%

The company has a current ratio of 2.46, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. The stock’s fifty day moving average is $58.26 and its two-hundred day moving average is $62.69.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.